Related Experiment Video
Updated: Aug 12, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
[Long-term therapy with a retard theophylline preparation]
Abstract:
The present study was conducted to investigate the therapeutic effect of long-term treatment with a slow-release theophylline preparation on the pulmonary functions FEV1 and peak exspiratory flow (PEF). A total of 908 patients took part in this open multicenter study. Treatment with the slow-release theophylline resulted in an increase of FEV1 and PEF of about 20% in asthma and between 11% and 14% in COPD. Apart from theophylline itself, the galenic nature of the slow-release formulation also contributed to the therapeutic effect.
Related Concept Videos
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Therapeutic Drug Monitoring: Drug Analysis Methods
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Oral Drug Delivery Systems: Continuous-Release Systems

